DRUG · Mapped RxNorm record
Ofatumumab
Normalized identity: ofatumumabView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab
NCT04869358
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedExploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Relapsing Multiple Sclerosisunresolved
Interventions
OfatumumabDRUG · verified · RxNorm: ofatumumab
Sponsors & collaborators
Novartis Pharmaceuticalslead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04869358 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.